The Immune Response to Crosslinked Tissue is Reduced in Decellularized Xenogeneic and Absent in Decellularized Allogeneic Heart Valves
Overview
Authors
Affiliations
Background: The degeneration and failure of xenogeneic heart valves, such as the Matrix P Plus valve (MP-V) consisting of decellularized porcine valves (dec-pV) and equine glutaraldehyde-fixed conduits (ga-eC) have been linked to tissue immunogenicity accompanied by antibody formation. In contrast, decellularized allograft valves (dec-aV) are well-tolerated. Here, we determined tissue-specific antibody levels in patients after implantation of MP-V or dec-aV and related them to valve failure or time period after implantation.
Methods And Results: Specific antibodies toward whole tissue-homogenates or alphaGal were determined retrospectively by ELISA analyses from patients who received MP-V with an uneventful course of 56.1 ± 5.1 months (n = 15), or with valve failure after 25.3 ± 14.6 months (n = 3), dec-aV for various times from 4 to 46 months (n = 14, uneventful) and from healthy controls (n = 4). All explanted valves were assessed histopathologically.MP-V induced antibodies toward both tissue components with significantly higher levels toward ga-eC than toward dec-pV (68.7 and 26.65 µg/ml IgG). In patients with valve failure, levels were not significantly higher and were related to inflammatory tissue infiltration. Anti-Gal antibodies in MP-V patients were significantly increased in both, the uneventful and the failure group. In contrast, in dec-aV patients only a slight tissue-specific antibody formation was observed after 4 months (6.24 µg/ml) that normalized to control levels after 1 year.
Conclusions: The strong humoral immune response to glutaraldehyde-fixed tissues is reduced in decellularized xenogeneic valves and almost absent in decellularized allogeneic tissue up to 4.5 years after implantation.
Sergeevichev D, Fomenko V, Chepeleva E, Kuznetsova E, Vaver A, Zhulkov M Polymers (Basel). 2025; 17(3).
PMID: 39940507 PMC: 11819663. DOI: 10.3390/polym17030305.
Decellularized aortic homografts versus mechanical composite grafts for aortic root replacement.
Andreeva A, Werner P, Coti I, Kocher A, Laufer G, Ehrlich M Eur J Cardiothorac Surg. 2024; 66(2).
PMID: 39178014 PMC: 11361793. DOI: 10.1093/ejcts/ezae314.
Andreeva A, Coti I, Werner P, Scherzer S, Kocher A, Laufer G J Clin Med. 2023; 12(21).
PMID: 37959179 PMC: 10650916. DOI: 10.3390/jcm12216713.
Graft rejection in paediatric congenital heart disease.
Harris A, Iacobazzi D, Caputo M, Bartoli-Leonard F Transl Pediatr. 2023; 12(8):1572-1591.
PMID: 37692547 PMC: 10485650. DOI: 10.21037/tp-23-80.
Biological Scaffolds for Congenital Heart Disease.
Harris A, Salih T, Ghorbel M, Caputo M, Biglino G, Carrabba M Bioengineering (Basel). 2023; 10(1).
PMID: 36671629 PMC: 9854830. DOI: 10.3390/bioengineering10010057.